36 related articles for article (PubMed ID: 20712528)
1. Human papillomavirus integration transforms chromatin to drive oncogenesis.
Karimzadeh M; Arlidge C; Rostami A; Lupien M; Bratman SV; Hoffman MM
Genome Biol; 2023 Jun; 24(1):142. PubMed ID: 37365652
[TBL] [Abstract][Full Text] [Related]
2. Towards Personalized Treatment Strategies for Esophageal Adenocarcinoma; A Review on the Molecular Characterization of Esophageal Adenocarcinoma and Current Research Efforts on Individualized Curative Treatment Regimens.
Hoefnagel SJM; Boonstra JJ; Russchen MJAM; Krishnadath KK
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638363
[TBL] [Abstract][Full Text] [Related]
3. LINC00997/MicroRNA 574-3p/CUL2 Promotes Cervical Cancer Development via Mitogen-Activated Protein Kinase Signaling.
Chu D; Liu T; Yao Y; Luan N
Mol Cell Biol; 2021 Jul; 41(8):e0005921. PubMed ID: 34031216
[TBL] [Abstract][Full Text] [Related]
4. Transcriptomic biomarkers for predicting response to neoadjuvant treatment in oesophageal cancer.
Lavery A; Turkington RC
Gastroenterol Rep (Oxf); 2020 Dec; 8(6):411-424. PubMed ID: 33442473
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant chemoradiation changes podoplanin expression in esophageal cancer patients.
Warnecke-Eberz U; Plum P; Schweinsberg V; Drebber U; Bruns CJ; Müller DT; Hölscher AH; Bollschweiler E
World J Gastroenterol; 2020 Jun; 26(23):3236-3248. PubMed ID: 32684738
[TBL] [Abstract][Full Text] [Related]
6. Predictive genetic markers in neoadjuvant chemoradiotherapy for locally advanced esophageal cancer: a long way to go. Review of the literature.
Gusella M; Pezzolo E; Modena Y; Barile C; Menon D; Crepaldi G; La Russa F; Fraccon AP; Pasini F
Pharmacogenomics J; 2018 Jan; 18(1):14-22. PubMed ID: 28607505
[TBL] [Abstract][Full Text] [Related]
7. Whole-exome tumor sequencing study in biliary cancer patients with a response to MEK inhibitors.
Ahn DH; Ozer HG; Hancioglu B; Lesinski GB; Timmers C; Bekaii-Saab T
Oncotarget; 2016 Feb; 7(5):5306-12. PubMed ID: 26683364
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic marker signature for esophageal cancer from transcriptome analysis.
Warnecke-Eberz U; Metzger R; Hölscher AH; Drebber U; Bollschweiler E
Tumour Biol; 2016 May; 37(5):6349-58. PubMed ID: 26631031
[TBL] [Abstract][Full Text] [Related]
9. Predicting the Response of Neoadjuvant Therapy for Patients with Esophageal Carcinoma: an In-depth Literature Review.
Tao CJ; Lin G; Xu YP; Mao WM
J Cancer; 2015; 6(11):1179-86. PubMed ID: 26516367
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant treatment for advanced esophageal cancer: response assessment before surgery and how to predict response to chemoradiation before starting treatment.
Bollschweiler E; Hölscher AH; Schmidt M; Warnecke-Eberz U
Chin J Cancer Res; 2015 Jun; 27(3):221-30. PubMed ID: 26157318
[TBL] [Abstract][Full Text] [Related]
11. High expression of survivin predicts poor prognosis in esophageal squamous cell carcinoma following radiotherapy.
Zhu H; Wang Q; Hu C; Zhang W; Quan L; Liu M; Xu N; Xiao Z
Tumour Biol; 2011 Dec; 32(6):1147-53. PubMed ID: 21826474
[TBL] [Abstract][Full Text] [Related]
12. The value of epigenetic markers in esophageal cancer.
Zhang XM; Guo MZ
Front Med China; 2010 Dec; 4(4):378-84. PubMed ID: 21107750
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of survivin mRNA is associated with a favorable prognosis following neoadjuvant radiochemotherapy in esophageal cancer.
Warnecke-Eberz U; Hokita S; Xi H; Higashi H; Baldus SE; Metzger R; Brabender J; Bollschweiler E; Mueller RP; Dienes HP; Hoelscher AH; Schneider PM
Oncol Rep; 2005 Jun; 13(6):1241-6. PubMed ID: 15870949
[TBL] [Abstract][Full Text] [Related]
14. Impact of ABCB1 C3435T polymorphism on lymph node regression in multimodality treatment of locally advanced esophageal cancer.
Narumiya K; Metzger R; Bollschweiler E; Alakus H; Brabender J; Drebber U; Hölscher AH; Warnecke-Eberz U
Pharmacogenomics; 2011 Feb; 12(2):205-14. PubMed ID: 21332314
[TBL] [Abstract][Full Text] [Related]
15. High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer.
Warnecke-Eberz U; Metzger R; Miyazono F; Baldus SE; Neiss S; Brabender J; Schaefer H; Doerfler W; Bollschweiler E; Dienes HP; Mueller RP; Danenberg PV; Hoelscher AH; Schneider PM
Clin Cancer Res; 2004 Jun; 10(11):3794-9. PubMed ID: 15173087
[TBL] [Abstract][Full Text] [Related]
16. Predicting response to neoadjuvant therapy in esophageal cancer.
Vallböhmer D; Brabender J; Grimminger P; Schröder W; Hölscher AH
Expert Rev Anticancer Ther; 2011 Sep; 11(9):1449-55. PubMed ID: 21929318
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers of response to preoperative chemoradiation in esophageal cancers.
Luthra R; Luthra MG; Izzo J; Wu TT; Lopez-Alvarez E; Malhotra U; Choi IS; Zhang L; Ajani JA
Semin Oncol; 2006 Dec; 33(6 Suppl 11):S2-5. PubMed ID: 17178277
[TBL] [Abstract][Full Text] [Related]
18. CUL2 and STK11 as novel response-predictive genes for neoadjuvant radiochemotherapy in esophageal cancer.
Metzger R; Heukamp L; Drebber U; Bollschweiler E; Zander T; Hoelscher AH; Warnecke-Eberz U
Pharmacogenomics; 2010 Aug; 11(8):1105-13. PubMed ID: 20712528
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
